Kevin Billingsley, MD, MBA, FACS
Professor of Surgery (Oncology)Cards
About
Research
Publications
2026
All Things Excellent Are as Difficult as They Are Rare
Mayo S, Billingsley K. All Things Excellent Are as Difficult as They Are Rare. Journal Of Clinical Oncology 2026, 44: 431-434. PMID: 41533991, DOI: 10.1200/jco-25-02119.Commentaries, Editorials and Letters
2025
Robotic Approach to Multivisceral Resection for Gastrointestinal Stromal Tumor With En Bloc Resection of the Stomach, Distal Pancreas, and Spleen: A Case Report
Bader J, Liu S, Billingsley K. Robotic Approach to Multivisceral Resection for Gastrointestinal Stromal Tumor With En Bloc Resection of the Stomach, Distal Pancreas, and Spleen: A Case Report. Cureus 2025, 17: e96479. PMID: 41384208, PMCID: PMC12691104, DOI: 10.7759/cureus.96479.Peer-Reviewed Original ResearchQuality of gastrointestinal surgical oncology care according to insurance status
Butensky S, Kerekes D, Bakkila B, Billingsley K, Ahuja N, Johnson C, Khan S. Quality of gastrointestinal surgical oncology care according to insurance status. Journal Of Gastrointestinal Surgery 2025, 29: 101961. PMID: 39800081, DOI: 10.1016/j.gassur.2025.101961.Peer-Reviewed Original Research
2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchAdjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchReasonable expansion of surgical candidates for HCC treatment
Butensky S, Billingsley K, Khan S. Reasonable expansion of surgical candidates for HCC treatment. Clinical Liver Disease 2024, 23: e0153. PMID: 38720794, PMCID: PMC11078523, DOI: 10.1097/cld.0000000000000153.Peer-Reviewed Original ResearchProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original Research
2023
Impact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchPhase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchHepatopancreatobiliary malignancies: time to treatment matters
Kerekes D, Frey A, Bakkila B, Johnson C, Becher R, Billingsley K, Khan S. Hepatopancreatobiliary malignancies: time to treatment matters. Journal Of Gastrointestinal Oncology 2023, 0: 0-0. PMID: 37201090, PMCID: PMC10186552, DOI: 10.21037/jgo-22-1067.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Kevin G. Billingsley, MD, MBA, is a surgical oncologist who specializes in the surgical treatment of gastrointestinal cancers. He treats tumors of the liver, pancreas, gall bladder, and bile ducts, including cholangiocarcinoma. Dr. Billingsley also has expertise in metastatic tumors in the liver.
Dr. Billingsley says he considers caring for cancer patients a privilege and a calling. He works closely with medical oncologists, gastroenterologists, interventional radiologists, and other specialists to coordinate care for his patients. He most values the relationships he develops with patients and their families through the course of the cancer care journey.
Dr. Billingsley serves as the chief medical officer for the Yale Cancer Center and Smilow Cancer Hospital and Care Centers, where he oversees quality and patient safety initiatives across the cancer care enterprise. He leads the improvement of multidisciplinary team structures, assists with facilities and space planning, and works closely with Yale New Haven Health System’s clinical leaders.
Dr. Billingsley’s research interests include gastrointestinal cancers with a particular emphasis on developing new multidisciplinary treatment strategies for metastatic colorectal cancer, and improving clinical outcomes following complex liver and pancreas operations. In his leadership role, his interests include the development of integrated academic health care systems, patient communication, and strategies to support clinician resilience.
Clinical Specialties
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineCancer
Learn More on Yale MedicineHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale MedicineSmall Intestine Adenocarcinoma
Learn More on Yale Medicine
Board Certifications
Surgery General
- Certification Organization
- AB of Surgery
- Original Certification Date
- 1997
Yale Medicine News
News & Links
News
- April 29, 2026Source: WTNH
Doctors at Yale Cancer Center mark major milestone in robotics surgeries
- March 11, 2026Source: Yale Insights: Health & Veritas with Howard P. Forman and Harlan M. Krumholz
Kevin Billingsley: The Making of the Modern Surgeon
- June 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting
- April 01, 2025
Yale Research Presented at 2025 Society of Surgical Oncology Annual Meeting
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Kevin Billingsley, MD, MBA, FACS - Toby Bressler, PhD, RN
Everyone Kevin Billingsley, MD, MBA, FACS - Toby Bressler, PhD, RN
Everyone Kevin Billingsley, MD, MBA, FACS - Toby Bressler, PhD, RN
Everyone Kevin Billingsley, MD, MBA, FACS - Toby Bressler, PhD, RN